Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 1/2 7Phase 1 6Phase 3 3Phase NA 1Phase 4 1Phase 2/3 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Leukemia 6Neuroblastoma 4Lymphoma 4Leukemia, Myeloid, Acute 4Melanoma 3Sarcoma 2Rhabdomyosarcoma 2Radiation Injuries 2Malignant mesenchymal tumor 2Lymphoma, Follicular 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Head and Neck Neoplasms 2Congenital Abnormalities 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Stomatitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1

Interventions

Dacarbazine 25Nivolumab 24pembrolizumab 19Ipilimumab 18Interferon-alpha 10trametinib 8Vemurafenib 8dabrafenib 7aldesleukin 7Temozolomide 7Introns 7Interferon alpha-2 6Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4cemiplimab 4binimetinib 4Radiotherapy 4Paclitaxel 4Granulocyte-Macrophage Colony-Stimulating Factor 4sargramostim 3encorafenib 3cobimetinib 3Vinblastine 3Surgical Procedures, Operative 3Specimen Handling 3Sodium Chloride 3Radiosurgery 3Opdualag 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Melanoma × sargramostim × Clear all
NCT01826864 2020-07-27

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Jonsson Comprehensive Cancer Center

Phase 3 Withdrawn
Dermatologic

Melanoma

NCT01989572 2020-07-07

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

National Cancer Institute (NCI)

Phase 3 Completed
815 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00769704 2016-07-13

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

BioVex Limited

Phase 3 Completed
437 enrolled 19 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡